• Home
  • Search Results
  • Human olfactory bulb neural stem cells mitigate movement disorders in a rat model of Parkinson's disease.

Human olfactory bulb neural stem cells mitigate movement disorders in a rat model of Parkinson's disease.

Journal of cellular physiology (2014-12-24)
Hany E S Marei, Samah Lashen, Amany Farag, Asmaa Althani, Nahla Afifi, Abd-Elmaksoud A, Shaymaa Rezk, Roberto Pallini, Patrizia Casalbore, Carlo Cenciarelli
ABSTRACT

Parkinson's disease (PD) is a neurological disorder characterized by the loss of midbrain dopaminergic (DA) neurons. Neural stem cells (NSCs) are multipotent stem cells that are capable of differentiating into different neuronal and glial elements. The production of DA neurons from NSCs could potentially alleviate behavioral deficits in Parkinsonian patients; timely intervention with NSCs might provide a therapeutic strategy for PD. We have isolated and generated highly enriched cultures of neural stem/progenitor cells from the human olfactory bulb (OB). If NSCs can be obtained from OB, it would alleviate ethical concerns associated with the use of embryonic tissue, and provide an easily accessible cell source that would preclude the need for invasive brain surgery. Following isolation and culture, olfactory bulb neural stem cells (OBNSCs) were genetically engineered to express hNGF and GFP. The hNFG-GFP-OBNSCs were transplanted into the striatum of 6-hydroxydopamin (6-OHDA) Parkinsonian rats. The grafted cells survived in the lesion environment for more than eight weeks after implantation with no tumor formation. The grafted cells differentiated in vivo into oligodendrocyte-like (25 ± 2.88%), neuron-like (52.63 ± 4.16%), and astrocyte -like (22.36 ± 1.56%) lineages, which we differentiated based on morphological and immunohistochemical criteria. Transplanted rats exhibited a significant partial correction in stepping and placing in non-pharmacological behavioral tests, pole and rotarod tests. Taken together, our data encourage further investigations of the possible use of OBNSCs as a promising cell-based therapeutic strategy for Parkinson's disease.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Retinoic acid, ≥98% (HPLC), powder
Sigma-Aldrich
DAPI, for nucleic acid staining
Sigma-Aldrich
G 418 disulfate salt, powder, BioReagent, suitable for cell culture
Sigma-Aldrich
G 418 disulfate salt solution, 50 mg/mL in H2O, 0.1 μm filtered, BioReagent, suitable for cell culture
Sigma-Aldrich
6-Hydroxydopamine hydrochloride, ≥97% (titration), powder
Sigma-Aldrich
Fluorescein, for fluorescence, free acid
Sigma-Aldrich
Methyl isothiocyanate, 97%
Sigma-Aldrich
G 418 disulfate salt, potency: ≥720 μg per mg (dried basis)
Ciclosporin, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
(±)-CPP, solid
Fluorescein, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
DL-Tyrosine, 99%
Tyrosine, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
G 418 disulfate salt, suitable for plant cell culture, BioReagent
Supelco
Methyl isothiocyanate, PESTANAL®, analytical standard
Ciclosporin for system suitability, European Pharmacopoeia (EP) Reference Standard

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

MilliporeSigma

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.